Related Experiment Videos
Continuous phrophylcatic anticonvulsants in selected childrens with febrile convulsions
Insights
Continuous prophylactic phenobarbitone or primidone significantly reduces the recurrence of febrile convulsions in high-risk children. This treatment is effective in preventing further seizures compared to no treatment.
Area of Science:
- Pediatrics
- Neurology
- Clinical Pharmacology
Background:
- Febrile convulsions are common in children.
- Recurrence risk is higher in children with specific risk factors.
- Effective prophylactic strategies are needed to prevent recurrent febrile seizures.
Purpose of the Study:
- To assess the recurrence rate of febrile convulsions.
- To evaluate the efficacy of continuous prophylactic phenobarbitone or primidone.
- To identify indications for continuous antiepileptic therapy.
Main Methods:
- A cohort of 108 children with risk factors for recurrence was studied.
- Children received continuous prophylactic phenobarbitone or primidone for at least 18 months.
- A comparison group of untreated children was observed.
Main Results:
- Only 17% of treated children experienced another fit.
- 59% of untreated children had recurrent febrile convulsions.
- The difference in recurrence rates was statistically significant (p < 0.0005).
Conclusions:
- Continuous prophylactic therapy with phenobarbitone or primidone is highly effective in preventing febrile convulsion recurrence.
- Treatment is recommended for children with prolonged/repeated initial fits or positive family history and neurological disorder.
- Further discussion on indications for long-term therapy is warranted.
Abstract:
The recurrence rate of febrile convulsions is assessed in 108 children who had had either prolonged or repeated initial fits or had both a positive family history and persisting neurological disorder. Only 7 of 40 (17%) who received continuous prophylactic phenobarbitone or primidone for at minimum of 18 months had another fit compared with 40 of 68 (59%) children who were untreated (p less than 0.0005). Indications for continuous therapy are discussed.